Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.66 USD | -0.06% | -11.75% | +55.02% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.02% | 1.32B | |
+11.56% | 116B | |
+12.37% | 106B | |
-7.09% | 23.89B | |
-3.11% | 21.58B | |
-10.90% | 18.96B | |
-40.50% | 16.96B | |
-13.67% | 16.33B | |
+7.08% | 14.14B | |
+33.56% | 12.02B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Special Call